Zai Lab Ltd (ZLAB) - Total Liabilities
Based on the latest financial reports, Zai Lab Ltd (ZLAB) has total liabilities worth $399.00 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Zai Lab Ltd cash conversion from operations to assess how effectively this company generates cash.
Zai Lab Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how Zai Lab Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Zai Lab Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Zai Lab Ltd Competitors by Total Liabilities
The table below lists competitors of Zai Lab Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ePlus inc
NASDAQ:PLUS
|
USA | $768.39 Million |
|
Wuhan PS Information Tech
SHE:300184
|
China | CN¥2.58 Billion |
|
BW LPG Limited
F:BW9
|
Germany | €1.23 Billion |
|
Polibeli Group Ltd Class A Ordinary Shares
NASDAQ:PLBL
|
USA | $5.14 Million |
|
Shell plc
LSE:SHEL
|
UK | GBX195.10 Billion |
|
Comet Holding AG
SW:COTN
|
Switzerland | CHF190.26 Million |
|
EMEIS SA
PA:EMEIS
|
France | €11.57 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥8.72 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Zai Lab Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ZLAB market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zai Lab Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zai Lab Ltd (2015–2024)
The table below shows the annual total liabilities of Zai Lab Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $344.86 Million | +43.58% |
| 2023-12-31 | $240.18 Million | +37.60% |
| 2022-12-31 | $174.54 Million | -24.11% |
| 2021-12-31 | $230.00 Million | +79.28% |
| 2020-12-31 | $128.29 Million | +112.08% |
| 2019-12-31 | $60.49 Million | +18.83% |
| 2018-12-31 | $50.91 Million | +251.96% |
| 2017-12-31 | $14.46 Million | -89.70% |
| 2016-12-31 | $140.46 Million | +334.73% |
| 2015-12-31 | $32.31 Million | -- |
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more